We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+7.57%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$1.84B
AUM Growth
+$214M
Cap. Flow
+$218M
Cap. Flow %
11.89%
Top 10 Hldgs %
45.79%
Holding
65
New
8
Increased
23
Reduced
12
Closed
3

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$129M
2
KYMR icon
Kymera Therapeutics
KYMR
+$80.3M
3
CYTK icon
Cytokinetics
CYTK
+$77.7M
4
RVMD icon
Revolution Medicines
RVMD
+$36.1M
5
RPTX
Repare Therapeutics
RPTX
+$29.7M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$88.8M
2
ARGX icon
argenx
ARGX
+$53M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$38.2M
4
KURA icon
Kura Oncology
KURA
+$28.4M
5
BDTX icon
Black Diamond Therapeutics
BDTX
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 98.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GLMD icon
51
Galmed Pharmaceuticals
GLMD
$5M
$6.35M 0.35%
9,998
– –
XFOR icon
52
X4 Pharmaceuticals
XFOR
$378M
$5.37M 0.29%
26,430
-7,266
-22% -$1.74M
AMRN
53
Amarin Corp
AMRN
$298M
$4.63M 0.25%
+55,000
New +$6.59M
CRIS icon
54
Curis
CRIS
$9.63M
$4.27M 0.23%
9,125
– –
FWP
55
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$4.03M 0.22%
647,299
– –
PHXM
56
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$3.91M 0.21%
62,500
– –
ELDN icon
57
Eledon Pharmaceuticals
ELDN
$260M
$3.34M 0.18%
195,326
+96,159
+97% +$947K
BLRX
58
BioLineRX
BLRX
$12.2M
$2.77M 0.15%
42,159
– –
VIRX
59
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.16M 0.12%
493,517
+419,376
+566% +$3.66M
RGLS
60
DELISTED
Regulus Therapeutics
RGLS
$1.65M 0.09%
321,748
+176,748
+122% +$1.16M
FSTX
61
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$1.26M 0.07%
235,293
– –
EXEL icon
62
Exelixis
EXEL
$13.4B
$374K 0.02%
15,300
– –
BDTX icon
63
Black Diamond Therapeutics
BDTX
$96.8M
– –
-378,788
Closed -$16M
SURF
64
DELISTED
Surface Oncology, Inc. Common Stock
SURF
– –
-2,038,528
Closed -$13.4M
PRNB
65
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
– –
-1,484,674
Closed -$88.8M
1 2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2020 Portfolio in Review

As of Q3 2020, BVF Inc held 65 positions worth $1.84B, up 13% from $1.62B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

BVF Inc deployed $218M of net new capital in Q3 2020, opening 8 new positions and adding to 23 existing holdings. Its largest new stake was Relay Therapeutics: 3,378,380 shares worth $144M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier.

On the sell side, the largest reduction was argenx, an estimated $53M trimmed.

  • BVF Inc's largest Q3 2020 buy was Relay Therapeutics: 3,378,380 shares worth $144M.
  • BVF Inc added most to Revolution Medicines in Q3 2020, an estimated $36.1M increase.
  • BVF Inc's biggest Q3 2020 reduction was argenx, cutting an estimated $53M.
  • BVF Inc fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $88.8M.
  • BVF Inc's ten largest holdings make up 46% of its $1.84B portfolio in Q3 2020.
  • BVF Inc opened 8 new positions and closed 3 in Q3 2020.
  • BVF Inc's portfolio value rose 13% quarter-over-quarter to $1.84B.

Based on BVF Inc's 13F filing for Q3 2020, filed 13 Nov 2020.